Current as of June 22, 2026

Short talks selected from proffered abstracts

PR001 **ELF3-driven epigenetic reprogramming creates ERK pathway dependency in SERD-resistant ER+ breast cancer**. Na Zhang. Dana-Farber Cancer Institute, Boston, MA, United States.

PR002 **Dark kinase dependency screening reveals STK17A as a previously unrecognized targetable vulnerability in EGFR-altered glioblastoma**. Eric Spinetti. STARX Therapeutics Inc, Miami, FL, United States.

PR003 **Targeting the "undruggable" oncogene CCNE1 using a molecular glue degrader in CCNE1 amplified cancers**. Nina Ilic-Widlund. Monte Rosa Therapeutics, Inc., Boston, MA, United States.

PR004 **enFoldX: AI classification of AlphaFold3-derived structural ensembles enables T cell specificity prediction**. Jonathan Levine. MSKCC, NEW YORK, NY, United States.

PR005 **JAB-BX600, a first-in-class EGFR-directed antiboEdy drug conjugate delivering a novel KRAS G12D inhibitor**. Andrea Wang-Gillam. Jacobio (US) Pharmaceuticals, Burlington, MA, United States.

PR006 **Patient-level prediction of oncology clinical trial outcomes using a calibrated pan-cancer foundation model for synthetic control arms and indirect treatment comparisons**. Samantha Liang. Unlearn.AI, Inc, San Francisco, CA, United States.

PR007 **Discovery of a Next-Generation KAT6A Inhibitor with an Improved Therapeutic Index and Reduced Hematotoxicity Risk**. Davide D'Alia. Qubit Pharmaceuticals, Paris, France.

PR008 **VBC106: A First-in-class FOLR1/MSLN Targeted Tri-specific Antibody Drug Conjugate (ADC) in Ovarian Cancer, Endometrial Cancer, Lung Adenocarcinoma and Beyond**. Jing Li. VelaVigo (Shanghai) Limited, Shanghai, China.

PR009 **DLL3 CAR-T and CAR-NK cell combination therapy promotes synergistic antitumor activity in small cell lung cancer**. Alan Bers. Dana-Farber Cancer Institute, Boston, MA, United States.

PR010 **Targeted degradation of cyclin T1 constrains transcription elongation and triggers tumour cell apoptosis**. Janice Wenzheng Neng. Department of Pharmacology, University of Cambridge, Cambridge CB2 1PD, UK Gurdon Institute, University of Cambridge, UK, Cambridge, United Kingdom.

PR011 **A first-in-class Pin1 degrader provides robust PKPD response and efficacy in PDAC models**. Morgan O'Shea. Larkspur Biosciences, Cambridge, MA, United States.

PR012 **GLIO-1 is a selective DHODH inhibitor that is effective in IDH-mutant gliomas and KDM6-mutated cancers**. Diana Shi. Harvard Medical School, Boston, United States.

PR013 **CDK4/6 bifunctional degraders overcome CDK4/6i resistance in breast cancer and demonstrate antitumor efficacy in additional tumor types**. Maechen Wang. Memorial Sloan Kettering Cancer Center, New York, NY, United States.

Poster Session A (To be presented on July 22 from 6:15-8:45 p.m.)

A001 **A Murine Translational Platform for ADC-Associated ILD Supports Rational Linker Optimization and Development of ARK-101, a Low-Toxicity HER2 ADC**. Suresh Anaganti. NJ Bio, Inc., Princeton, NJ, United States.

A002 **Paired PDX-PDXO Models Serve an Integrated Preclinical Platform for High-Throughput Payload Screening and ADC Drug Development**. Ludovic Bourre. Crown Bioscience, San Diego, CA, United States.

A003 **Novel ATR inhibitor antibody conjugates with potent single payload antitumor activity for personalized medicine**. Martin Duplessis. DCx Biotherapeutics, Saint Laurent, QC, Canada.

A004 **Precision degrader-antibody conjugates (pDACs) with a SMARCA2/4 dual payload as targeted therapeutics for acute myeloid leukemia**. Ryan Holmes. Prelude Therapeutics, Wilmington, DE, United States.

A005 **VBC106: A First-in-class FOLR1/MSLN Targeted Tri-specific Antibody Drug Conjugate (ADC) in Ovarian Cancer, Endometrial Cancer, Lung Adenocarcinoma and Beyond**. Jing Li. VelaVigo (Shanghai) Limited, Shanghai, China.

A006 **VBC104: A First-in-class CD79b/CD20 Targeted Bi-specific Antibody Drug Conjugate (ADC) with Superior Efficacy vs 1st line CD79b ADC in DLBCL, RT, FL, MCL, MZL and Beyond**. Jing Li. VelaVigo (Shanghai) Limited, Shanghai, China.

A007 **Sacituzumab Govitecan as a Potential Strategy for Sensitizing Cisplatin-Resistant HNSCC to Senolytic Treatment**. Natalie Luffman. Virginia Commonwealth University, Richmond, VA, United States.

A008 **ERBB2 activating mutations define a delivery-permissive state enhancing trastuzumab deruxtecan activity in HER2-non-amplified breast cancer**. Sharanya Nag. Memorial Sloan Kettering Cancer Center, New York, New York, NY, United States.

A009 **Preclinical safety and efficacy QP101: A novel HER2-targeting dual payload ADC combining topoisomerase I (TOP1) and cyclin dependent kinase 7 (CDK7) inhibitors**. Kiyean Nam. Qurient Co. Ltd., Seongnam, Korea, Rep.

A010 **Post-translational modifications of transferrin receptor are novel therapeutic targets for Antibody-Drug Conjugates in Small Cell Lung Cancer**. Amanda Riley. Fred Hutch Cancer Center, Seattle, WA, United States.

A011 **Trastuzumab deruxtecan kills skin and uveal melanoma in vivo by HER2-independent payload release**. Elif Tanaydin. University of Gothenburg, Gothenburg, Sweden.

A012 **Preclinical Development of LGR4/5/6–FOLR1 Bispecific Antibody-Drug Conjugates for the Treatment of High-Grade Serous Ovarian Cancer**. Yukimatsu Toh. University of Texas, Houston, TX, United States.

A013 **Preclinical Development of a Humanized CD44v9-Directed Antibody-Drug Conjugate for Treatment-Refractory Breast Cancer**. Naoto Ueno. University of Hawai'i Cancer Center, Honolulu, HI, United States.

A014 **CAN020, a Trop2-targeting, dual-payload ADC from CanWell Pharma**. Shaoshan Wang. CanWell Pharma, Inc., Woburn, MA, United States.

A015 **JAB-BX600, a first-in-class EGFR-directed antiboEdy drug conjugate delivering a novel KRAS G12D inhibitor**. Andrea Wang-Gillam. Jacobio (US) Pharmaceuticals, Burlington, MA, United States.

A016 **High drug-to-antibody ratio (DAR) anti-TROP2 degrader-antibody conjugate (DAC) demonstrated poor solubility at high dose level leading to the fast clearance in mice**. Victor Yip. Genentech, South San Francisco, CA, United States.

A017 **A novel TROP2 targeting dual action bispecific tumor immunity enhancing ADC (TIE-ADC) that simultaneously eliminates cancer cells and immunosuppressor cells to overcome immunosuppression to enhance anti- tumor immune response in TNBC**. Shiva Bhowmik. TRIO Pharmaceuticals, Inc., San Diego, CA, United States.

A018 **A Novel CD33 and TRAIL-R2 Targeting Bispecific Antibody Sowing Selective Elimination of Leukemic Blasts With No Harm to Normal Myeloid and Other Immune Cells to Treat Relapsed/Refractory Acute Myeloid Leukemia**. Shiva Bhowmik. TRIO Pharmaceuticals, Inc., San Diego, CA, United States.

A019 **Targeted CNS Oncology Using Multispecific DNA-Based Therapeutics**. Emily Lin. Taipei Medical University and Hospital, Taipei, Taiwan.

A020 **Engineering developability of anti-CD3 scFv-based multispecific T-cell engagers**. Robert Pejchal. Adimab LLC, Lebanon, NH, United States.

A021 **Enhancing NK cell immunotherapy in non-small cell lung cancer using dual-antigen targeting Tri-Specific Killer Engagers (TriKEs/TriKE PACCs)**. Rachel Steinmetz. University of Minnesota, Minneapolis, MN, United States.

A022 **Agentic AI–Driven Knowledge Graph Centrality with Reciprocal Rank Fusion for Interactive Discovery of Cancer Driver Genes and Pathways**. Dony Ang. Siloam Therapeutics, La Habra, CA, United States.

A023 **Using an agentic AI research platform for rare cancer drug discovery: Case of rhabdoid tumors**. Reed Bender. Lantern Pharma, Dallas, TX, United States.

A024 **FastBindRank, a novel, scalable method for high-fidelity virtual screening of ultra-large chemical libraries idendtifies novel HDAC11 inhibitors**. Jiawei Dai. Yale Cancer Center, New Haven, CT, United States.

A025 **Real-World Data–Driven Target Discovery in Advanced NSCLC**. Aaron Hardin. Guardant Health, Palo Alto, CA, United States.

A026 **In-silicoPhase III Clinical Trial of Avelumab Plus Axitinib Versus Sunitinib in Advanced Renal Cell Carcinoma Using Machine Learning Model Transfer Approach**. Elshad Hasanov. Division of Medical Oncology, Department of Internal Medicine, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States.

A027 **Artificial intelligence for detection of treatment-related adverse events using electronic health records in oncology: Focus on Sub-Saharan African (SSA) countries.** Elinda Kuhoga. Muhimbili University of Health and Allied Sciencex, Dar-Es-Salaam, Tanzania.

A028 **enFoldX: AI classification of AlphaFold3-derived structural ensembles enables T cell specificity prediction**. Jonathan Levine. MSKCC, NEW YORK, NY, United States.

A029 **AI-Driven Network-Based Discovery on TCGA-PAAD Identifies KRAS-Axis Drug-Repurposing Targets for Pancreatic Cancer Interception**. Jianfu Li. Mayo Clinic, Jacksonville, FL, United States.

A030 **Patient-level prediction of oncology clinical trial outcomes using a calibrated pan-cancer foundation model for synthetic control arms and indirect treatment comparisons**. Samantha Liang. Unlearn.AI, Inc, San Francisco, CA, United States.

A031 **Large language models ensemble deciphers spatial proteogenomic landscapes to identify a novel trop2-cd47 co-targeting axis in non-small cell lung cancer**. Ellen McNeeley. University of Alabama at Birmingham, Birmingham, AL, United States.

A032 **Analysis of health records and genetics data to identify drug effects on cancer**. Rachel Melamed. UMass Lowell, Lowell, MA, United States.

A033 **Integratingcell-SELEX anddeeplearning method fordiscovery ofhigh-affinityaptamerstargetingcholangiocarcinoma**. Sourav Pal. Mayo Clinic, Jacksonville, FL, United States.

A034 **Repurposing adult clinical trials for pediatric target discovery using the CURE AI foundation model**. Neil Pfister. Numenos and the University of Alabama at Birmingham, Birmingham, AL, United States.

A035 **Diagnostic Accuracy of Virtual Programmed Death Ligand-1 Immunohistochemistry in Head and Neck Squamous Cell Carcinoma using Artificial Intelligence**. Charles Jeffrey Tan. Princess Margaret Cancer Center, Toronto, ON, Canada.

A036 **Smart Health Screening in Identification of Individuals at High Cancer Risk Using Artificial Intelligence**. Aida Yavari Kondori. Mashhad University of Medical Sciences, Mashhad, Iran, Islamic Rep.

A037 **Drug Development Using Machine Learning Approches: The Therapeutic Impact of Golnar on Inhibition of Tumor Growth in Colorectal Cancer**. Aida Yavari Kondori. Mashhad University of Medical Science, Mashhad, Iran, Islamic Rep.

A038 **Graph Neural Network Identification of Conserved Adaptive Resistance Circuits Across Glioblastoma Multiforme and KRAS-Mutant Lung Cancer**. Shivi Kumar. University of Pennsylvania, Dallas, TX, United States.

A039 **Physics-Informed Multi-Scale Modeling Identifies Redox–Membrane Stability Dependencies as a Therapeutic Vulnerability in Residual Glioblastoma Multiforme**. Shivi Kumar. University of Pennsylvania, Dallas, TX, United States.

A040 **Network Analysis and Deep Learning Identify Cascade Vulnerabilities in Glioblastoma Stem Cell Plasticity**. Darsh Dadhich. Hillsborough High School, Hillsborough, NJ, United States.

A041 **Glyco-Immune Checkpoint Activation in Inflammatory Breast Cancer Defines a Targetable Immune Evasion Program**. Ecem Kalemoglu. RUTGERS- Jersey City Medical Center, Jersey City, NJ, United States.

A042 **Identifying actionable dsRNA biomarkers from sense-antisense transcript pairs**. Otto Morris. Recursion Pharmaceuticals, London, United Kingdom.

A043 **The NF Target Hub: Connecting Transcriptomic Data to Targets in Neurofibromatosis**. Kara Quaid. The Children's Tumor Foundation, New York City, NY, United States.

A044 **Decoding the endometriosis immune–pain axis: A single-cell pipeline for neuroimmune hub discovery and drug prioritization**. Ariana Rahman. Mayo Clinic, Phoenix, AZ, United States.

A045 **In-silico based approach to characterize a group of small-molecule inhibitors of checkpoint CHK1, CHK2, WEE1 protein kinases for drug discovery**. Ashok Varma. Advanced Centre for Treatment, Research, and Education in Cancer, Navi Mumbai, Maharashtra, 410210, India Homi Bhabha National Institute, Anushaktinagar, Mumbai, Maharashtra, 400094, India, Navi Mumbai, India.

A046 **CLDN18.2 Expression in PDAC: KRAS Independence and Stage IV Prognostic Value**. Sacha El Khoury. The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

A047 **Targeting mono-adp-ribosyltransferase 1 (ART1) suppresses tumor growth and oncogenic signaling in colorectal cancer**. Fnu Mimansa. Albert Einstein College of Medicine, Bronx, NY, United States.

A048 **Oncolytic virotherapy as a novel therapeutic strategy in prostate cancer**. Ayodeji Ojetunde. Medserve-LUTH Cancer Centre, Lagos University Teaching Hospital, Lagos, Nigeria.

A049 **Rational grafting of p53TAD onto CTPR scaffolds generates potent p53-MDM2 antagonists**. Yawei Qi. University of Cambridge, Cambridge, United Kingdom.

A050 **Determining extracellular domain of EpCAM in the tumor niche for cancer diagnosis and prognosis of therapy response**. Han-Chung Wu. Institute of Cellular and Organismic Biology, Academia Sinica, Taiwan, Taiwan.

A051 **Optimization of Dual Combination [DOX][NIR] Nanomedicine: Effect of Size Tuning on Photophysical Behavior and Photothermal Efficiency for Enhanced Anti-Tumor Activity**. Fatima Abbas. University of Arkansas at Little Rock, little rock, AR, United States.

A052 **Sol-Moiety: A Generalizable Platform for Solubility-Driven Drug Delivery**. Arvin Karbasi. University of California, Los Angeles, Los Angeles, TX, United States.

A053 **Discovery and modular design of CDK12–DDB1 molecular glues for targeted Cyclin K degradation**. Andrii Monastyrskyi. Moffitt Cancer Center, Tampa, FL, United States.

A054 **Molecular glue discovery enabled by targeted degron display**. Zhe Zhuang. Stanford University, Stanford, CA, United States.

A055 **In situ intratumoral microdosing and spatial profiling enable rapid clinical evaluation of novel therapeutics and predict response in glioblastoma**. oliver jonas. Brigham and Women's Hospital, Boston, MA, United States.

A056 **Network-integrated clinical trial navigation with ctDNA profiling improves early-phase trial access: Final results from the PANNA-COTA study**. Anthony Joshua. Kinghorn Cancer Centre, St Vincents Hospital, Sydney, Australia.

A057 **Real-World Target Trial Emulation of FLAURA Trial Using InfinityAI: First-Line Osimertinib versus First-Generation EGFR Tyrosine Kinase Inhibitors in Advanced EGFR-Mutant NSCLC**. Abbas Shojaee. Guardant Health, Palo Alto, CA, United States.

A058 **Demographics, genomic testing, and JAK-inhibitor (JAKi) utilization in a novel, U.S. community oncology prospective registry for essential thrombocythemia (ET) and myelofibrosis (MF)**. Christer Svedman. N-Power Medicine, Stockholm, Sweden.

A059 **Phase I study of the PKMYT1 inhibitor RP-6306 (lunresertib) in combination with carboplatin and paclitaxel for recurrent p53-abnormal ovarian and uterine cancer (GyneRep / OZUHN-019)**. Laura Venegas. Princess Margaret Cancer Centre, Toronto, ON, Canada.

A060 **Targeting metabolic–DNA repair vulnerabilities in SDHB- and FH-deficient renal cell carcinoma with the novel alkylating agent KL-50**. Suparna Basu. Yale University, New Haven, CT, United States.

A061 **Application of CRISPR–Cas9 Technology in the Treatment of Chronic Lymphocytic Leukemia with Mutations P53 gene**. Manole Cojocaru. Titu Maiorescu University of Bucharest, Faculty of Medicina, Bucharest, Romania.

A062 **Selective USP10 inhibition by GL-458 re-sensitizes platinum-resistant non-small cell lung cancer through DNA damage response disruption**. Sadaf Dorandish. WSU, Detroit, MI, United States.

A063 **Application of CRISPR–Cas9 Technology in the Treatment of Chronic Lymphocytic Leukemia with Mutations P53 gene**. Aurelian Udristioiu. Titu Maiorescu University of Bucharest, Faculty of Medical Assistance-Targu Jiu, Targu Jiu, Romania.

A064 **Application of CRISPR–Cas9 Technology in the Treatment of Chronic Lymphocytic Leukemia with Mutations P53 gene**. Aurelian Udristioiu. Titu Maiorescu University of Bucharest, Faculty of Medical Assistance-Targu Jiu, Targu Jiu, Romania.

A065 **The Role of miR-100 in lung cancer cell line: Relevance to cancer biology and potential therapy**. Basil Alotaibi. King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), RIYADH, Saudi Arabia.

A066 **Methyl N-[5-(3'-iodobenzoyl)-1H-benzimidazol-2-yl]carbamate: A potent, safe, and theranostic approach to microtubule-targeted cancer therapy**. Janina Baranowska-Kortylewicz. University of Nebraska Medical Center, Omaha, NE, United States.

A067 **Combined Top1 and CHK Inhibitor Dual-Payload Strategy for Synergistic Reversal of Tumor Drug Resistance**. Tiejun Bing. ICE Biosciences InC., Beijing, China.

A068 **Multi-omics validated KRASi-resistant cell lines for combination and sequential drug treatment discovery**. Tiejun Bing. ICE Biosciences InC., Beijing, China.

A069 **The rational design of innovative dual COX-2/TP modulators as a multitarget strategy to stop cancer progression and metastasis**. Francesca Boccato. University of Turin, Turin, Italy.

A070 **Discovery of a Next-Generation KAT6A Inhibitor with an Improved Therapeutic Index and Reduced Hematotoxicity Risk**. Davide D'Alia. Qubit Pharmaceuticals, Paris, France.

A071 **Catalyzing TBXT as a therapeutic target through an integrated discovery pipeline**. Lee Dolat. Chordoma Foundation, Durham, NC, United States.

A072 **Structure-based drug design targeting DNA topoisomerase II for cancer therapy**. Xuesen Dong. University of British Columbia, Vancouver, BC, Canada.

A073 **ONM-421, a pH-responsive polymer-drug conjugate nanoparticle for the antigen-independent delivery of MMAE to solid tumors by exploiting the tumor acidic microenvironment**. Ruolan Han. OncoNano Medicine, Inc., Dallas, TX, United States.

A074 **Styrene maleic acid lipid particles (SMALPs) as chemotherapeutic nanocarriers: biophysical characterisation, cellular uptake, and intracellular drug delivery in cancer cells.** Jushta Jaiswal. University of Warwick, Coventry, United Kingdom.

A075 **The myokine irisin directly inhibits COX-2.** Wonchung Lim. Cheongju University, Cheongju, Korea, Rep.

A076 **Seeing the Drug and Seeing What It Is Doing: Integrated Spatial PK/PD Analysis for Hybrid and Next-Generation Oncology Therapeutics**. Mark Lim. AmberGen Inc., Billerica, MA, United States.

A077 **Multi-pathway inhibition and synergistic anticancer activity of novel biguanides in triple negative breast cancer models**. Julie Liu. UCLA, Los Angeles, CA, United States.

A078 **TP101: First-in-class cancer stem cell–targeted small molecule combination therapy for epithelial malignancies**. Cody McHale. Tract Bio, Charlotte, NC, United States.

A079 **Structure-guided discovery of first-in-class TRIB2 small-molecule inhibitors for therapy-resistant neuroendocrine prostate cancer**. JITENDER MONGA. Henry Ford Health System, Detroit, MI, United States.

A080 **Activation of hSSB2/1 by BCN077 Induces Tumor-Selective Mitotic Catastrophe While Protecting Irradiated Epithelium: A New Therapeutic Paradigm for Expanding the Cancer Treatment Window**. Andrew Norris. BCN Biosciences, Inglewood, CA, United States.

A081 **Multi-omics integration and network pharmacology identify shared transcriptomic signatures across breast cancer, hepatocellular carcinoma, and ovarian cancer: in silico discovery of a novel phytochemical lead**. Souhrid Sarkar. University of Glasgow, Glasgow, GA, United Kingdom.

A082 **AP3-guided biological SAR enables discovery of ACR-2316, a novel clinical-stage WEE1/PKMYT1 inhibitor designed for CDK1/2 and PLK1 pathway activation**. Lei Shi. Acrivon Therapeutics Inc., Watertown, MA, United States.

A083 **Integrated multi-omic analysis and CRISPR screening identify GPX2 as a critical vulnerability in high-risk lung adenocarcinoma**. Akul Singhania. Tempus AI, Inc., Chicago, IL, United States.

A084 **Cloperastine inhibits glycolysis and fatty acid metabolism that drives electron transport chain in tongue cancer**. Sanjeev Waghmare. Advanced Centre for Treatment Research and Education in Cancer, Navi Mumbai, India.

A085 **Ogremorphin Induces Ferroptosis in Primary Human Glioblastoma Neurospheres**. Aaron Wasserman. Michigan State University College of Human Medicine, East Lansing, MI, United States.

A086 **AI-assisted identification and lab-based validation of novel hedgehog pathway inhibitors targeting the downstream GLI transcription effectors**. Kevin Williams. North Carolina Central University, Durham, NC, United States.

A087 **Calcitriol enhances chemotherapy response but fails to overcome established resistance in breast cancer models via VDR-dependent mechanisms**. Sirin Adham. Sultan Qaboos University, Muscat, Oman.

A088 **SLC39A6-targeted combination therapy to reverse CAF-induced resistance in HER2+ breast cancer using a microfluidic platform**. Zeina Habli. University of Pittsburgh, Pittsburgh, PA, United States.

A089 **ADT-1004: A mechanistically distinct pan-RAS inhibitor with the potential to escape resistance and mitigate on-target toxicities that limit efficacy and safety of other RAS inhibitors**. Gary Piazza. Auburn University, Auburn, AL, United States.

A090 **Therapy sequencing and capivasertib response in hormone receptor-positive, HER2-negative metastatic breast cancer (HR+/HER2- MBC)**. Emanuelle Rizk. Beth Israel Deaconess Medical Center, Boston, MA, United States.

A091 **Overcoming Microenvironment-Mediated Chemoresistance in Acute Megakaryoblastic Leukemia through JAK Inhibition and 3D Niche Modeling**. Akira SHIMADA. Jichi Medical University, Shimotuke, Japan.

A092 **Early Prediction of Imatinib Resistance in Chronic Myeloid Leukemia: Development of an Ex Vivo Diagnostic Approach**. Nipanshi Tyagi. Jawaharlal Nehru University, New Delhi, India.

Poster Session B (To be presented on July 23 from 6:15-8:45 p.m.)

B001 **Preclinical evaluation of novel synthetic derivatives of tamoxifen in hormone receptor positive breast cancer growth and drug resistance**. SARAH CRAWFORD. Southern Connecticut State University, New Haven, CT, United States.

B002 **Dissecting cellular heterogeneity and altered cell states in castration resistant prostate cancer**. Julia Gattozzi. Stony Brook University, Stony Brook, NY, United States.

B003 **VEGFR3-AKT Signaling Drives Acquired Resistance to Darovasertib in GNAQ/GNA11-Mutant Uveal Melanoma**. Dongyu Han. University of Texas at El Paso, El Paso, TX, United States.

B004 **Analysis of proteomic changes in enzalutamide-resistant prostate cancer cells and identification of potential therapeutic targets for drug repurposing**. Chidi Molokwu. Bradford Institute of Health Research, Bradford, United Kingdom.

B005 **ADT-030, a novel PDE10 inhibitor that blocks RAS and β-catenin signaling with robust and durable antitumor activity and potential to mitigate resistance and on-target toxicities of monospecific RAS inhibitors**. Gary Piazza. Auburn University, Auburn, AL, United States.

B006 **Identification of possible biomarkers for acquired resistance against anti EGFR treatment regimen in a patient derived NSCLC model in vivo**. Julia Schueler. Charles River Discovery Germany GmbH, Freiburg, Germany.

B007 **ELF3-driven epigenetic reprogramming creates ERK pathway dependency in SERD-resistant ER+ breast cancer**. Na Zhang. Dana-Farber Cancer Institute, Boston, MA, United States.

B008 **The Sum of Its Parts: The Prevalence of Contribution of Effect through an Evaluation of Combination Clinical Trial Regimens of Immune Checkpoint Inhibitors and the VEGF Tyrosine Kinase Inhibitor Axitinib**. Jordan Weiss. Dana Farber Cancer Institute, Boston, MA, United States.

B009 **Machine Learning-Assisted Epigenetic Profiling Reveals SOX2 Promoter Methylation Associated with CDK1 Dysregulation and Therapeutic Targeting in Breast Cancer**. Bushra Khan. JAMIA MILLIA ISLAMIA, NEW DELHI, India.

B010 **Therapeutic targeting of PRC1 complexes to induce neuroblastoma differentiation**. Nathaniel Mabe. Purdue University, West Lafayette, IN, United States.

B011 **Single-molecule protein footprinting with Fiber-seq resolves coordinated chromatin states across regulatory domain**. Keith Maier. EpiCypher, Inc., Durham, NC, United States.

B012 **FFPE-CUT&Tag transcription profiling in patient biopsies reveals novel druggable pathways in lymphoma**. Morgan Oatley. EpiCypher, Inc., Durham, NC, United States.

B013 **KAT6A/B Inhibition Durably Reprograms Neuroblastoma Cell State to Enhance Retinoid Response and GD2-Directed Immunotherapy.** Nina Weichert-Leahey. Dana-Farber Cancer Institute, Boston, MA, United States.

B014 **Therapeutic Reversal of Tumor Cell Plasticity by EHF mRNA Delivery in Prostate Cancer**. Giuseppina Carbone. Institute of Oncology Research, Bellinzona, Switzerland.

B015 **RNA interference via siRNA-lipid conjugates is a safe and effective approach for MCL1-targeted therapy in triple-negative breast cancer**. Nina Cassidy. Vanderbilt University, Nashville, TN, United States.

B016 **Locally Injectable CASP Hydrogel for Sustained Co-Delivery of Temozolomide and an EGFR-Targeted Tandem Peptide siRNA System for Synergistic Glioblastoma Therapy**. Jordan Kinnitt. Clemson University, Clemson, SC, United States.

B017 **CLD-401, a Systemic Gene Medicine for In Situ IL-15SuperagonistDelivery: Driving NKandγδT Cell-Mediated TumorKilling**. Duong Nguyen. Calidi Biotherapeutics, San Diego, CA, United States.

B018 **CLD-501, an In Situ T Cell Engager Targeting TROP2: Reprogramming Solid Tumors to Generate Their Own Immunotherapy**. Eric Poma. Calidi Biotherapeutics, SAN DIEGO, CA, United States.

B019 **Application of CRISPR–Cas9 technology in the treatment of chronic lymphocytic leukemia with mutations P53 gene**. Aurelian Udristioiu. in Titu Maiorescu University of Bucharest, Faculty of Medical Assistance-Targu Jiu, Targu Jiu, Romania.

B020 **Immune, signal transduction, endocrine, cell growth and death, and neural signaling pathways are associated with the paclitaxel excipient polyoxyl 35 castor oil in PBMCs: implications for neurotoxic adverse side effects of chemotherapy**. Esther Chavez-Iglesias. University of California San Francisco, San Francisco, CA, United States.

B021 **A novel FcγR+ cDC1 activation state drives therapeutic efficacy of TIGIT and PD-L1 co-blockade**. Ellen Duong. Genentech, South San Francisco, CA, United States.

B022 **Menin Inhibition and Leukemia Immunogenicity: A Novel Epigenetic Mechanism to Sensitize KMT2A-Rearranged Infant Leukemia to T-Cell-Mediated Cytotoxicity**. Aru Narendran. University of Calgary, Calgary, AB, Canada.

B023 **Mechanistic effects of Terfezia boudieri and its nanoformulation on cell cycle regulation and apoptosis in breast cancer models**. Roua Nouh. Biotechnology department , School of science and Engineering- The American University in Cairo, Cairo, Egypt.

B024 **Cisplatin primes an interferon-driven CD8^{+} central memory T cell program to enable oncolytic virotherapy in gastrointestinal cancer malignancies**. Joseph Parker. Mayo Clinic Florida, Jacksonville, FL, United States.

B025 **Temporal Substate Flow and Multimodal Prediction Reveal Druggable Branch Points of EGFR TKI Resistance in NSCLC**. Michael Previte. Element Biosciences, San Diego, CA, United States.

B026 **PRISM mapping of the drug modality landscape: A systematic 900 cancer cell line reference of diverse therapeutic approaches**. Matthew Rees. Broad Institute of MIT & Harvard, Cambridge, MA, United States.

B027 **CRISPR screens identify thioredoxin reductase 1 as a target for inducing disulfidptosis in IDH1-mutant glioma models**. Dean Singleton. The University of Auckland, Auckland, New Zealand.

B028 **Identification of novel compounds that mediate transcriptional repression of estrogen receptor alpha gene ESR1 in breast cancer**. Jayalakshmi Sridhar. Xavier University of Louisiana, New Orleans, LA, United States.

B029 **Structures of human telomerase with BIBR1532 reveal novel mechanism of inhibition**. Yuqing Wang. UCLA, Los Angeles, CA, United States.

B030 **Fentanyl engages a GPCR-Neu1 signaling axis with divergent effects on pancreatic cancer cell behavior**. Abdulrahman Yaish. Queen's University, Kingston, ON, Canada.

B031 **MetAP2 inhibition by evexomostat (SDX-7320) decreases EZH2 and c-Myc and significantly prolongs survival in enzalutamide-resistant and neuroendocrine prostate cancer models**. Peter Cornelius. SynDevRx, Inc, Cambridge, MA, United States.

B032 **A High-Throughput Microfluidic Platform with Lab Automation and AI-Driven Morphological Profiling for Mechanism-of-Action Prediction of Anticancer Compounds**. Jenna McCormack. Xellar Biosystems, Boston, MA, United States.

B033 **Understanding the use and interpretation of duration of response endpoints in non-small cell lung cancer**. Brittany McKelvey. LUNGevity Foundation, Bethesda, MD, United States.

B034 **A case of myxoid variant of angiomatoid fibrous histiocytoma treated with tocilizumab before surgical resection**. Beatriz Mella Soares Pessoa. University of Connecticut, Farmington, CT, United States.

B035 **Restoring topoisomerase I inhibitor sensitivity in pediatric rhabdomyosarcoma using a pH-sensitive peptide-exatecan conjugate**. Shahyan Rehman. Yale School of Medicine, New Haven, CT, United States.

B036 **Allele Specific Characteristics of KRASQ61 Mutated Gastrointestinal Malignancies and Clinical Outcomes and Transcriptomic Features**. Sacha El Khoury. The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

B037 **Convergent DNA damage and chromatin instability signatures as pharmacogenomic enrichment biomarkers for first-line Gemcitabine-Cisplatin ± Durvalumab in advanced biliary tract cancer: Beyond TMB/MSI**. Moonho Kim. University of Ulsan College of Medicine, Gangneung Asan Hospital, Gangneung, Korea, Rep.

B038 **Butyrylcholinesterase in uveal melanoma: Functional insights into a druggable prognostic biomarker**. Keyi Lyu. University of Nebraska Medical Center, Omaha, NE, United States.

B039 **Targeted Degradation of PD-L1 by Selective ER Translocation Inhibitors (SERTIs)**. Thomas Bell. ASERTI Pharmaceutical, Reno, NV, United States.

B040 **Hold-to-Kill: RIPTAC Expanding Induced Proximity from Target Engagement to Therapeutic Window**. Tiejun Bing. ICE Biosciences InC., Beijing, China.

B041 **PROTAC-mediated degradation of TACC3 sensitizes tumors to taxanes and induces apoptosis in FGFR3–TACC3 fusion cancers**. Eugen Dhimolea. Albert Einstein College of Medicine, New York City, NY, United States.

B042 **Clinical development and mechanism of action of LRK-4189, a first-in-class degrader of the lipid kinase PIP4K2C**. Krista Goodman. Larkspur Biosciences, Belmont, MA, United States.

B043 **Integrated organoid screening approaches enable preclinical assessment of protein degrader efficacy and target engagement**. Marten Hornsveld. Crown Bioscience, Leiden, Netherlands.

B044 **Targeting the "undruggable" oncogene CCNE1 using a molecular glue degrader in CCNE1 amplified cancers**. Nina Ilic-Widlund. Monte Rosa Therapeutics, Inc., Boston, MA, United States.

B045 **Targeted degradation of cyclin T1 constrains transcription elongation and triggers tumour cell apoptosis**. Janice Wenzheng Neng. Department of Pharmacology, University of Cambridge, Cambridge CB2 1PD, UK Gurdon Institute, University of Cambridge, UK, Cambridge, United Kingdom.

B046 **A first-in-class Pin1 degrader provides robust PKPD response and efficacy in PDAC models**. Morgan O'Shea. Larkspur Biosciences, Cambridge, MA, United States.

B047 **dCBP-30: A rationally designed, orally bioavailable, near-linkerless PROTAC for potent CBP/p300 degradation**. Praveen Tiwari. Krantz Family Center for Cancer Research, Massachusetts General Hospital, Department of Medicine, Harvard Medical School, Boston, MA, United States.

B048 **CDK4/6 bifunctional degraders overcome CDK4/6i resistance in breast cancer and demonstrate antitumor efficacy in additional tumor types**. Maechen Wang. Memorial Sloan Kettering Cancer Center, New York, NY, United States.

B049 **Discovery of a small-molecule degrader targeting the intracellular immune checkpoint CISH**. Hao Xie. Mayo Clinic, Rochester, MN, United States.

B050 **Novel, conformational target discovery in TKI-resistant non-small cell lung cancer**. Faraz Choudhary. Immuto Scientific, Cambridge, MA, United States.

B051 **Targeted proteomics for parallel ADC biomarker screening: a pilot feasibility study within an Australian precision oncology program**. Nicholas McNamee. ProCan - Children's Medical Research Insitute, University of Sydney, Sydney, NSW, Australia.

B052 **The Kinase Library: A global atlas of the human protein kinome and its applications in drug discovery**. Tomer Yaron-Barir. Dana-Farber Cancer Institute, Boston, MA, United States.

B053 **[18F]Fluoroglutamine PET radiotracer as a noninvasive biomarker of TP53-driven serine synthesis pathway activity in breast cancer**. Darshi Shah. Stony Brook Medicine, Stony Brook, NY, United States.

B054 **Alpha-Emitter vs. Beta-Emitter PSMA-Targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer - A Systematic Review of Meta-Analyses**. Hina Zubair. Guthrie Robert Packer Hospital, Sayre, PA, United States.

B055 **Targeting LSD1 for anti-PD1 therapy resistance mechanism in Head and Neck Cancer for future therapy**. Manish Bais. Boston University, Boston, MA, United States.

B056 **DLL3 CAR-T and CAR-NK cell combination therapy promotes synergistic antitumor activity in small cell lung cancer**. Alan Bers. Dana-Farber Cancer Institute, Boston, MA, United States.

B057 **Evaluation of immune checkpoint inhibitors and targeted therapies ex vivo in live tumor fragments from core biopsies and resections accurately predicts response in the clinic**. Sean Caenepeel. Elephas Biosciences, Madison, WI, United States.

B058 **IMNN-001, a novel immune-oncology therapeutic delivering IL-12 to ovarian tumor and its microenvironment, facilitating immune reprogramming and survival benefit in the clinic.** Douglas Faller. IMUNON, Lawrenceville, NJ, United States.

B059 **Discovery of a "preparative survival checkpoint (signal-1 prime)" in B cells hijacked by cancer to confer chemotherapy resistance**. Jaewoong Lee. Korea university, Seoul, Korea, Rep.

B060 **Multimodal engineering of human mucosal-associated invariant T (MAIT) cells for enhanced cancer immunotherapy in liver cancer**. Yan-Ruide Li. University of California, Los Angeles, Los Angeles, CA, United States.

B061 **Harnessing stem cell-engineered CAR-NKT cells for universallow-toxicity autoimmune therapy**. Yan-Ruide Li. University of California, Los Angeles, Los Angeles, CA, United States.

B062 **Gene-transfer-resistant and biocontained synthetic organisms for discovery and controlled drug delivery**. Akos Nyerges. Harvard Medical School, Boston, MA, United States.

B063 **A gene-editable human regulatory T-cell platform reveals USP22 as a regulator of FOXP3 stability and IFN-γ production.** Ajita Singh. Sai Life Sciences, Watertown, MA, United States.

B064 **Changes in tumormyeloid cellcomposition in patients with advanced pancreatic adenocarcinoma treated withlenvatinibplus pembrolizumab in second-line or later therapy**. Brandon Smaglo. UT MD Anderson Cancer Center, Houston, TX, United States.

B065 **RSK is a driver of immune suppression and tumor progression in basal-like breast cancer.** Ashley Spirrison. Vanderbilt University, Nashville, TN, United States.

B066 **Human Tumor-on-Chip Platform for Mechanistic Investigation of Immune Exclusion and Immunotherapy Response in the Tumor Microenvironment**. Yu-Chieh Yuan. Xellar Biosystems, Boston, MA, United States.

B067 **Boosting immunogenic tumour cell death via nanotherapeutic targeting of the Stanniocalcin 1 phagocytosis checkpoint for enhanced cancer immunotherapy**. Jianqin Lu. Dept. of Pharmacology/Toxicology, R. Ken Coit College of Pharmacy The University of Arizona, TUCSON, AZ, United States.

B068 **A sphingolipid-derived paclitaxel nanovesicle enhances efficacy of combination therapies in triple-negative breast cancer and pancreatic cancer**. Jianqin Lu. Dept. of Pharmacology/Toxicology, R. Ken Coit College of Pharmacy The University of Arizona, TUCSON, AZ, United States.

B069 **Pharmacodynamic evidence of Wnt/β-catenin inhibition by tegavivint, a TBL1-directed transcriptional modulator, in advanced hepatocellular carcinoma: a phase 1 study**. Aundrietta Duncan. Iterion Therapeutics, Houston, TX, United States.

B070 **ATX-295, a Novel KIF18A Inhibitor, as a Therapeutic in Chromosomally Instable Tumors**. Laura Ghisolfi. Accent Therapeutics, Lexington, MA, United States.

B071 **TRβ Agonists as a First-in-Class Oncology Therapeutic Strategy: Broad Anti-Tumor Activity with Proof-of-Concept in Breast Cancer**. Noelle Gillis. University of Vermont, Burlington, VT, United States.

B072 **SHY-ONC6, a first-in-class oral inhibitor of the proteasome 19S regulatory particle ATPases, drives tumor regression across solid and hematological xenograft models**. Yaron Hadari. SHY Therapeutics, LLC, Valhalla, NY, United States.

B073 **Rationale and Development of First-in-class Lysosome Disrupting Agent for Solid Tumours**. Anthony Joshua. Princess Margaret Cancer Centre, Toronto, ON, Canada.

B074 **Evaluation of a small molecule, AP-232, as a splicing factor inhibitor of U2 auxiliary factor 1 (U2AF1) in leukemia cells**. Mona Kazemi Sabzvar. The University of Tennessee Health Science Center, Memphis, TN, United States.

B075 **Selective targeting of inosine monophosphate dehydrogenase-2 impairs brain metastatic potential while preserving immune cell function**. Agata Kieliszek. McMaster University, Hamilton, ON, Canada.

B076 **Novel artesunate trimer derivatives as antitumor therapies for hepatocellular carcinoma**. Xiaohua Kong. The University of Texas at El Paso, EL PASO, TX, United States.

B077 **EMI-1725 Demonstrates Broad Antagonist Activity Against Drug-Resistant Androgen Receptor Mutations and Tumor Growth Suppression in Preclinical Models of Metastatic Castration-Resistant Prostate Cancer**. Steven Kregel. Loyola University Chicago, Maywood, IL, United States.

B078 **A brain-penetrant tumor-selective EGFR inhibitor for glioblastoma**. Sarah Lee. UCLA, Los Angeles, CA, United States.

B079 **Small-molecule inhibition of CBFB::MYH11 in chemoresistant inv(16) acute myeloid leukemia**. Thuy-An Nguyen. University of Virginia, Charlottesville, VA, United States.

B080 **Targeting tumor metabolism in breast cancer using LDHA inhibition to enhance chemotherapy response**. Khushboo Pathania. UIPS, Panjab Univeristy and University of Nottingham, Chandigarh and Nottingham, UK, India.

B081 **Lysyl oxidase inhibitor LXG6403 creates ferroptosis vulnerability in triple-negative breast cancer**. Ozge Saatci. Medical University of South Carolina, Charleston, United States.

B082 **Lysyl oxidase inhibitor LXG6403 effectively suppresses tumor progression and overcomes therapeutic resistance in clear cell renal cell carcinoma**. Ozgur Sahin. Medical Uiversity of South Carolina, Charleston, SC, United States.

B083 **GLIO-1 is a selective DHODH inhibitor that is effective in IDH-mutant gliomas and KDM6-mutated cancers**. Diana Shi. Harvard Medical School, Boston, United States.

B084 **Dark kinase dependency screening reveals STK17A as a previously unrecognized targetable vulnerability in EGFR-altered glioblastoma**. Eric Spinetti. STARX Therapeutics Inc, Miami, FL, United States.

B085 **Selective oral STK17A inhibitor UMF814A targets a previously unrecognized dark kinase vulnerability in spliceosome-mutant MDS and AML**. Eric Spinetti. STARX Therapeutics Inc, Miami, FL, United States.

B086 **Aspartyl/asparaginyl beta-hydroxylase (ASPH) blockade abrogates doxorubicin induced chemoresistance in chondrosarcoma**. Richard Terek. Brown University, Providence, RI, United States.

B087 **Dual MET/AXL inhibition suppresses hepatocellular carcinoma through tumour cell–intrinsic and microenvironment-dependent mechanisms**. Chenjing Zhu. Jiangsu Cancer Hospital, Nanjing, China.

B088 **A cryptic alternative bound state of HDAC6 drives mutation- and ligand-dependent remodeling of inhibitor interaction**. Paul Fong. Duke University, Durham, NC, United States.

B089 **Targeting metabolic vulnerabilities in cancer through structure-guided discovery of novel malic enzyme inhibitors**. Ben Krinkel. University of Auckland, New Zealand, New Zealand.

B090 **Label-free Raman molecular histology enables patient-tissue metabolic stratification for target selection in lung adenocarcinoma**. Katherine Zhao. SuperVision Medicine Co.,Ltd; Columbia University, Wuxi, China.

B091 **Synthetic Lethality of G6PD Deficiency and Asparaginase for Colorectal Cancer Therapy**. Alejandro Gutierrez. St. Jude Children's Research Hospital, Memphis, TN, United States.

B092 **MBD4 LOF defines a synthetic lethal therapeutic state targetable by ATR inhibition rather than PARP in high-grade serous ovarian cancer**. Fahad Kiani. CrisPRO.ai, Brooklyn, NY, United States.

B093 **Combinatorial CRISPR screening reveals synthetic lethal and suppressor interactions in RTK signaling and glycosylation networks**. Subin Kim. The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

B094 **Suppressing ERG-driven oncogenesis by mRNA-based delivery of an intracellular mini-body targeting a unique protein methylation site in ERG fusion-positive prostate cancer**. Carlo Catapano. Institute of Oncology Research, Bellinzona, Switzerland.

B095 **Targeted inhibition of SLC2A5 prevents tumour growth and metastasis**. Jody Groenendyk. University of Alberta, Edmonton, AB, Canada.

B096 **Targeting NONO as a therapeutic strategy for metastatic castration-resistant prostate cancer (mCRPC)**. Gaelle Mercenne. Talus Bio, Seattle, WA, United States.

B097 **Microfluidics-enabled asymmetric lipid vesicles for targeted delivery of RNA-based cancer vaccines in colorectal cancer**. Sabiruddin Mirza. School of Engineering and Applied Science, Harvard University, Cambridge, United States.

B098 **Ad5.F35-GUCY2C-PADRE vaccine safely induces dose-dependent immune responses associated with reduced recurrences in patients with GUCY2C-expressing GI cancers at high risk of relapse**. Adam Snook. Thomas Jefferson University, Philadelphia, PA, United States.